文献速递血管炎

检测MPO与PR3相关性ANCA血管炎循环补体活化产物

Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
PubMed 文献 · Arthritis Rheumatol · 2019-10-08

该研究纳入98例AAV患者(45例MPO-ANCA阳性、53例PR3-ANCA阳性)及35名健康对照,比较EDTA管加或不加Futhan处理血浆中Bb、C3a、C5a、sC5b-9、备解素和C4d水平。结果显示MPO阳性与PR3阳性AAV均存在补体活化,活化谱随疾病活动度及可能随ANCA血清型而异,Futhan可减少体外补体活化。

要点

  • MPO阳性活动期AAV的C3a、C5a、sC5b-9高于健康对照。
  • PR3阳性活动期AAV的C3a、C5a、sC5b-9、C4d高于健康对照。
  • Futhan处理可减少体外补体活化,使测定更准确。

核心结论

  • 补体活化在MPO阳性AAV和PR3阳性AAV中均存在,其活化谱随疾病活动度及可能随ANCA血清型不同。

研究设计与样本

  • 研究纳入98例AAV患者(45例MPO-ANCA阳性、53例PR3-ANCA阳性)和35名健康对照。
  • 血浆采用EDTA管采集,分加或不加100 μg/ml Futhan处理,以酶联免疫吸附试验测定Bb、C3a、C5a、sC5b-9、备解素和C4d。
  • 组间比较采用Wilcoxon两样本检验,配对数据采用配对符号秩检验。

主要发现

  • 与健康对照相比,MPO阳性活动期AAV患者C3a(P < 0.0001)、C5a(P = 0.0004)、sC5b-9(P = 0.0007)水平升高。
  • MPO阳性AAV缓解期Bb(P = 0.001)、C3a(P < 0.0001)、sC5b-9(P = 0.003)水平高于健康对照。
  • 与健康对照相比,PR3阳性活动期AAV患者C3a(P < 0.0001)、C5a(P = 0.002)、sC5b-9(P = 0.0001)、C4d(P = 0.005)水平升高,缓解期C3a(P < 0.0001)和C4d(P = 0.007)仍升高。
  • 两种ANCA血清型患者中,活动期与缓解期之间任何补体分析物均无显著差异;配对样本中缓解期sC5b-9显著低于活动期。
  • 长期缓解且未治疗患者C5a显著降低;不加Futhan处理的对照与患者样本中Bb、C5a、sC5b-9的中位数及个体值明显高于加Futhan处理者。

临床怎么用

  • 检测循环补体活化产物时应使用含Futhan的EDTA采血管以减少体外活化。
  • MPO阳性与PR3阳性AAV的补体活化谱可能不同,解读结果时需结合ANCA血清型与疾病活动度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is accumulating evidence that complement activation is important in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) pathogenesis. This study was undertaken to investigate complement activation in AAV with myeloperoxidase (MPO) positivity and AAV with proteinase 3 (PR3) positivity after determining optimal methods for measuring activated complement factors in circulation. METHODS: Participants included 98 patients with AAV (45 MPO-ANCA positive, 53 PR3-ANCA positive) and 35 healthy controls. Plasma was obtained from blood collected using EDTA tubes, with or without 100 μg/ml Futhan. Levels of Bb, C3a, C5a, soluble C5b-9 (sC5b-9), properdin, and C4d were measured by enzyme-linked immunosorbent assay. Group comparisons were made using Wilcoxon's 2-sample test. Paired data were analyzed using a matched pairs signed rank test. RESULTS: Compared to healthy controls, certain complement analyte levels were high in patients with active AAV with MPO positivity, including C3a (P < 0.0001), C5a (P = 0.0004), and sC5b-9 (P = 0.0007). During remission, levels of Bb (P = 0.001), C3a (P < 0.0001), and sC5b-9 (P = 0.003) were higher. Compared to healthy controls, C3a (P < 0.0001), C5a (P = 0.002), sC5b-9 (P = 0.0001), and C4d (P = 0.005) levels were higher in patients with active AAV with PR3 positivity; levels of C3a (P < 0.0001) and C4d (P = 0.007) were also higher duriing remission. There were no significant differences in any complement analyte for either ANCA serotype between patients with active disease and those with disease in remission. Among patients with paired samples, sC5-9 levels were significantly lower during disease remission compared to active disease. C5a was significantly lower among patients with disease in long-term remission who were not receiving therapy. For Bb, C5a, and sC5b-9, median levels and individual values were considerably higher in control and patient samples processed without Futhan compared to those processed with Futhan. CONCLUSION: Complement activation occurs in both MPO-positive AAV and PR3-positive AAV. The complement activation profile differs according to disease activity and possibly ANCA serotype. Futhan reduces in vitro complement activation and provides a more accurate measurement.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wu EY, McInnis EA, Boyer-Suavet S, et al. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019. PMID: 31215772. doi:10.1002/art.41011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。